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ABSTRACT
High-affinity and selective antagonists that are able to block the
actions of both endogenous and synthetic agonists of G protein–
coupled receptors are integral to analysis of receptor function
and to support suggestions of therapeutic potential. Although
there is great interest in the potential of free fatty acid receptor
4 (FFA4) as a novel therapeutic target for the treatment of type II
diabetes, the broad distribution pattern of this receptor suggests
it may play a range of roles beyond glucose homeostasis in
different cells and tissues. To date, a single molecule, 4-methyl-
N-9H-xanthen-9-yl-benzenesulfonamide (AH-7614), has been
described as an FFA4 antagonist; however, its mechanism of
antagonism remains unknown. We synthesized AH-7614 and a
chemical derivative and demonstrated these to be negative
allosteric modulators (NAMs) of FFA4. Although these NAMs did
inhibit FFA4 signaling induced by a range of endogenous and
synthetic agonists, clear agonist probe dependence in the nature
of allostericmodulation was apparent. Although AH-7614 did not
antagonize the second long-chain free fatty acid receptor, free
fatty acid receptor 1, the simple chemical structure of AH-7614
containing features found in many anticancer drugs suggests
that a novel close chemical analog of AH-7614 devoid of FFA4
activity, 4-methyl-N-(9H-xanthen-9-yl)benzamide (TUG-1387),
will also provide a useful control compound for future studies
assessing FFA4 function. Using TUG-1387 alongside AH-7614,
we show that endogenous activation of FFA4 expressed by
murine C3H10T1/2 mesenchymal stem cells is required for
induced differentiation of these cells toward a more mature,
adipocyte-like phenotype.
Introduction
Free fatty acid receptor 4 (FFA4) (Davenport et al., 2013;
Milligan et al., 2017), which is also still frequently designated
as GPR120 (Hirasawa et al., 2005), was identified in 2005 as a
G protein–coupled receptor (GPCR) responsive to long-chain
free fatty acids (Hirasawa et al., 2005). Since then, not least
because essential and other polyunsaturated v-3 fatty acids
with health-promoting properties are among the most
potent fatty acid activators of this receptor (Hirasawa
et al., 2005; Christiansen et al., 2015), there has been
strong interest in better understanding the biologic func-
tions of FFA4 and in its potential as a therapeutic target
(Liu et al., 2015; Li et al., 2016). Because reported effects of
FFA4 activation include regulation of glucose homeostasis
(Oh et al., 2014; Azevedo et al., 2016), regulation of release
of incretins and satiety-regulating hormones (Hirasawa
et al., 2005), modulation of insulin sensitivity (Oh et al.,
2010, 2014; Azevedo et al., 2016), and potential effects on
weight gain (Ichimura et al., 2012; Mo et al., 2013; Azevedo
et al., 2016), a large focus of studies on FFA4 has centered
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ABBREVIATIONS: AH-7614, 4-methyl-N-9H-xanthen-9-yl-benzenesulfonamide; aLA, a linolenic acid; BRET, bioluminescence resonance energy
transfer; Cpd A, 3-[2-chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecane-9-acetic acid; d6-DMSO, d6-dimethylsulfoxide; DMEM, Dulbecco’s
modified Eagle’s medium; ESI-HRMS, electrospray ionization-high-resolution mass spectrometry; eYFP, enhanced yellow fluorescent protein; FBS, fetal
bovine serum; FFA1, free fatty acid receptor 1; FFA4, free fatty acid receptor 4; GPCR, G protein–coupled receptor; GSK137647A, 4-methoxy-N-(2,4,6-
trimethylphenyl)-benzenesulfonamide; HBSS, Hanks’ balanced salt solution; hFFA1, human FFA1; hFFA4, human FFA4; HPLC, high-performance liquid
chromatography; IBMX, 3-isobutyl-1-methylxanthine; IID, 100 nM insulin, 500 mM 3-isobutyl-1-methylxanthine and 10 nM dexamethasone; mFFA4,
murine FFA4; mp, melting point; NAM, negative allosteric modulator; pIC50, negative logarithm of IC50; PPARg, peroxisome proliferator activator
receptor g; RT-qPCR, reverse-transcription quantitative polymerase chain reaction; TUG-1197, 2-(3-(pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole
1,1-dioxide; TUG-1387, 4-methyl-N-(9H-xanthen-9-yl)benzamide; TUG-1506, 4-methyl-N-(9H-thioxanthen-9-yl)benzenesulfonamide; TUG-770, 4-[2-[2-
(cyanomethyl)phenyl]ethynyl]-2-fluorobenzenepropanoic acid; TUG-891, 4-[(4-fluoro-4’-methyl[1,1’-biphenyl]-2-yl)methoxy]-benzenepropanoic
acid.
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on the possibility that agonists of this receptor might be
useful antidiabetic agents (Cornall et al., 2014; Zhang and
Leung, 2014; Moran et al., 2016). However, it is clear that the
expression pattern of FFA4, which includes high levels in the
lung, in macrophage populations, and in various cancer cell
types (Houthuijzen, 2016; Milligan et al., 2017), indicates a
broader set of roles and potential for therapeutic interven-
tions targeting this receptor (Milligan et al., 2017). This
has resulted in screening for, and the identification of, a
number of series of FFA4 agonist ligands (Milligan et al.,
2015, 2017), although chemical diversity within these series
has, until recently (e.g., Sparks et al., 2014; Azevedo et al.,
2016), remained rather limited and based on carboxylate-
containing ligands that resemble synthetic fatty acids.
FFA4 has been shown to be a potential regulator of adipocyte
development and differentiation (Gotoh et al., 2007), poten-
tially via increasing expression of the adipogenic transcrip-
tion factor peroxisome proliferator activator receptor g
(PPARg) (Hasan et al., 2015; Song et al., 2016). Moreover,
adipocyte differentiation from bone marrow mesenchymal
stem cells has also been suggested to be promoted by FFA4
(Gao et al., 2015).
A major challenge in studying all aspects of both in vivo
and ex vivo regulation of cell and tissue function by FFA4 is
that the endogenous fatty acid ligands that are able to
activate the receptor are present ubiquitously. Furthermore,
being bound extensively by plasma proteins, the concentra-
tions and disposition of “free” fatty acids are often challeng-
ing to define (Ulven and Christiansen, 2015), as is the extent
of receptor activation in situ that can be attributed to such
systemic, circulating fatty acids. As such, alongside various
“knockdown” and “knockout” strategies (Alvarez-Curto et al.,
2016), well characterized and selective blockers of FFA4
function would be highly valuable tool compounds to fur-
ther unravel biologic roles of FFA4. To date, a single FFA4
“antagonist” has been described. Compound 39 (Sparks et al.,
2014) [now designated AH-7614 (4-methyl-N-9H-xanthen-9-
yl-benzenesulfonamide) by commercial vendors] was shown
to block effects of both a fatty acid and a synthetic FFA4
agonist in FFA4-transfected U2OS human osteosarcoma
cells, and to antagonize both FFA4-mediated insulin secre-
tion from mouse insulinoma MIN6 cells and the secretion of
GLP-1 from the human intestinal cell line NCI-H716 (Sparks
et al., 2014).
Herein, we examine the antagonistic properties of AH-7614,
and a small number of chemical derivatives, at FFA4. This
demonstrates that AH-7614 is able to inhibit FFA4-mediated
signals induced by a range of distinct fatty acids and synthetic
FFA4 agonist ligands across all endpoints tested. Analysis
of the mechanism of antagonism indicates that these com-
pounds are negative allosteric modulators (NAMs) of FFA4
function, which display “probe dependence” in the nature of
their inhibitory properties, depending on the specific agonists
they are inhibiting. This work also identifies a close chemical
derivative of AH-7614 that lacks antagonistic activity at
FFA4, which, given the current lack of knowledge about
potential off-target effects of AH-7614, will be a useful tool
in defining FFA4-specific biologic effects. We have demon-
strated the utility of this approach in assessing the role of
FFA4 in adipogenesis of murine C3H10T1/2 mesenchymal
stem cells.
Materials and Methods
Materials and Compounds. Unless otherwise stated, all bio-
chemicals and reagents were from Sigma-Aldrich (St. Louis, MO).
Tissue culture reagents and buffers were from Life Technologies Inc
(Paisley, UK). TUG-891 [4-[(4-fluoro-4’-methyl[1,1’-biphenyl]-2-yl)-
methoxy]-benzenepropanoic acid] was synthesized as described
previously (Shimpukade et al., 2012). Compound 34 (TUG-1197)
(2-(3-(pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole1,1-dioxide)
was synthesized as described by Azevedo et al. (2016). GSK137647A
[4-methoxy-N-(2,4,6-trimethylphenyl)-benzenesulfonamide] was synthe-
sized according to Sparks et al. (2014). TUG-770 (4-[2-[2-(cyanomethyl)-
phenyl]ethynyl]-2-fluorobenzenepropanoic acid) was synthesized as
described previously (Christiansen et al., 2013). Cpd A (3-[2-chloro-5-
(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecane-9-acetic acid) was
synthesized essentially as described by Chelliah et al. (2014). AH-7614/
compound 39 was synthesized as follows: xanthone (100 mg, 0.5 mmol)
was dissolved inmethanol (10ml), sodium borohydride (96mg, 2.6mmol)
was added portionwise over 20 minutes, and the reaction was stirred at
room temperature for 24 hours. The reaction was partitioned between
ethyl acetate and water. The two phases were separated, and the aque-
ous phase was extracted twice with ethyl acetate. The organic phases
were combined, washed with brine, dried over anhydrous sodium
sulfate, filtered, and concentrated. The crude product was used directly
in the next step without further purification. p-Toluenesulfonamide
(95 mg, 0.56 mmol) was added to the crude mixture, followed by acetic
acid (5ml). The reactionwas stirred for 2 hours at room temperature. The
reaction was partitioned between water and ethyl acetate. The two
phases were separated, and the aqueous phase was extracted twice with
ethyl acetate. The organic phases were combined, washed with brine,
dried over anhydrous sodium sulfate, filtered, and concentrated. The
crude product was purified by silica gel flash chromatography (ethyl
acetate/petroleum ether, 1:4) to give the desired compound as a white
solid (136 mg, 77% over two steps): mp 194.1–195.5°C; 1H NMR
(400 MHz, CDCl3) 7.83–7.75 (m, 2H), 7.33 (d, J 5 8.0 Hz, 2H), 7.30–
7.23 (m, 2H), 7.15 (dd, J5 7.8, 1.4 Hz, 2H), 7.08 (dd, J5 8.3, 1.0 Hz, 2H),
6.99 (td, J5 7.7, 1.2 Hz, 2H), 5.77 (d, J5 8.6 Hz, 1H), 4.91 (d, J5 8.6 Hz,
1H), 2.47 (s, 3H); 13C NMR (100 MHz, CDCl3): 151.3, 143.6, 138.6, 129.8,
129.5, 127.2, 123.6, 120.4, 116.7, 49.2, 21.6; electrospray ionization-
high-resolution mass spectrometry (ESI-HRMS) m/z: calculated
C20H17NaO3S [M1Na
1]: 374.0821; found: 374.0804; high-performance
liquid chromatography (HPLC) 99.7%. The data agree with those of Liu
et al. (2013). TUG-1387 [4-methyl-N-(9H-xanthen-9-yl)benzamide] was
synthesized as follows: 4-Methylbenzamide (205mg, 1.5 mmol) and 9H-
xanthen-9-ol (150mg, 0.76mmol) were suspended in acetic acid (1.5 ml)
and heated to 90°C. The compounds went into solution after 1 minute,
anda fewminutes later, awhite solid started to precipitate. The reaction
was heated overnight and cooled to room temperature, filtered and
washed with acetic acid (0.5 ml), then washed with cold ethyl acetate
(3 ml). Subsequent drying gave the product as a white solid (180 mg,
75%): mp 229.8–231.6°C; tR 5 12.88 minutes (HPLC purity: 98.7%);
1H NMR [400 MHz, d6-dimethylsulfoxide (d6-DMSO)] d 9.36 (d, J 5
8.6 Hz, 1H), 7.82 (d, J5 8.2 Hz, 1H), 7.40 (d, J5 7.6 Hz, 1H), 7.37–7.31
(m, 1H), 7.26 (d, J5 8.0 Hz, 1H), 7.20–7.11 (m, 1H), 6.55 (d, J5 8.6 Hz,
1H), 2.34 (s, 1H); 13C NMR (101 MHz, d6-DMSO) d 165.7, 150.6, 141.3,
131.1, 130.0, 128.9, 128.8, 127.5, 123.4, 121.9, 116.1, 43.0, 20.9; ESI-HRMS
calculated for C21H17NnaO2 [M1Na
1]: 338.1151, found: 338.1163. The
data agreewith those of Patrick andDolan (1973). TUG-1506 (4-methyl-
N-(9H-thioxanthen-9-yl)benzenesulfonamide) was synthesized as fol-
lows: A 250-ml flask was charged with thioxanthone (2.0 g, 9.4 mmol),
tetrahydrofuran (30ml), andmethanol (10ml). The solutionwas stirred
at room temperature, andNaBH4 (1.07 g, 28.3mmol) was added slowly.
The initially yellow reaction mixture slowly turned orange. After
45 minutes, the solution was diluted with water and extracted three
times with ethyl acetate. The combined organic phases were washed
with brine, dried over sodium sulfate, and concentrated to give the crude
alcohol as an orange solid (2.02 g) thatwas used immediately in the next
step: 1H NMR (400MHz, d6-DMSO) d 7.70 (d, J5 7.6 Hz, 2H), 7.50 (dd,
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J 5 7.7, 0.9 Hz, 2H), 7.36 (td, J 5 7.5, 1.2 Hz, 2H), 7.28 (td, J 5 7.5,
1.0 Hz, 2H), 6.40 (d, J5 5.8 Hz, 1H), 5.19 (d, J5 5.7 Hz, 1H); 13C NMR
(101MHz, d6-DMSO) d 139.0, 130.8, 126.8, 126.6, 126.4, 125.3, 69.3. The
data agree with those of Cozzi and Zoli (2008). 9H-Thioxanthen-9-ol
(2.02 g, 9.4 mmol) and p-toluenesulfonamide (2.22 g, 10.4 mmol) were
dissolved in acetic acid (30 ml) and stirred at room temperature
overnight. The resulting precipitate was isolated by filtration and
washed first with cold acetic acid and then cold petroleum ether to
afford the product as a white solid (2.2 g, 64%): mp 158.7–163.9°C; tR5
12.94 minutes (HPLC purity: 99.0%); Rf 5 0.40 (EtOAc:PE, 1:1);
1H
NMR (400MHz,d6-DMSO) d 8.76 (d,J5 8.4Hz, 1H), 7.65 (d,J58.3Hz,
2H), 7.50–7.46 (m, 2H), 7.37–7.28 (m, 4H), 7.28–7.19 (m, 4H), 5.23 (d,J5
8.4 Hz, 1H), 2.35 (s, 3H); 13C NMR (101 MHz, d6-DMSO) d 142.4, 138.8,
134.9, 132.2, 129.3, 127.3, 126.8, 126.7, 126.5, 126.3, 56.5, 20.9; ESI-
HRMS calculated for C20H17NNaO2S2 [M1Na
1]: 390.0593, found:
390.0585. The data agree with those of Tamura et al. (1977).
Cell Culture. HEK293T cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum (FBS) at 37°C and 5% (v/v) CO2. Flp-In T-REx 293 cell
lines, generated to inducibly express various tagged versions of hu-
man FFA4 (hFFA4), human FFA1 (hFFA1), or murine FFA4 (mFFA4)
following treatment with doxycycline, were maintained in DMEM
supplemented with 10% (v/v) FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 200mg/ml hygromycin B. Human brain astrocytoma
1321N1 cells stably transfected with hFFA1 were grown in DMEM
supplemented with 10% (v/v) FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 400 mg/ml G418. To study adipogenesis, murine
C3H10T1/2 cells (Tang et al., 2004) were grown in DMEM containing
10% (v/v) FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin in a
37°C incubator with 5% (v/v) CO2. Cells in 10-cm dishes were dif-
ferentiated with IID [100 nM insulin, 500mM3-isobutyl-1-methylxanthine
(IBMX), and 10 nM dexamethasone] for 5 days in the presence/
absence of vehicle [0.1% (v/v) DMSO], 10 mM AH-7614, or 10 mM
TUG-1387.
Plasmids. Plasmids encoding either the human (short isoform) or
mouse FFA4 receptors with enhanced yellow fluorescent protein
(eYFP) or the related fluorescent protein mVenus fused to their C
terminus and incorporating an N-terminal FLAG epitope tag in the
pcDNA5 FRT/TO expression vector were generated as previously
described (Hudson et al., 2013; Butcher et al., 2014; Alvarez-Curto
et al., 2016; Prihandoko et al., 2016).
b-Arrestin-2 Interaction Assay. b-Arrestin-2 recruitment to
either human or mouse isoforms of FFA4 was measured using a
bioluminescence resonance energy transfer (BRET)–based approach.
HEK293T cells were cotransfected with eYFP-tagged forms of each
receptor in a 4:1 ratio with a b-arrestin-2 Renilla luciferase plasmid
using polyethylenimine. Cells were then transferred into white 96-well
plates at 24 hours post-transfection. At 48 hours post-transfection,
cells werewashedwithHanks’ balanced salt solution (HBSS) and then
incubated in fresh HBSS prior to the assay. Cells were preincubated
for 15 minutes with HBSS supplemented with vehicle [1% (v/v)
DMSO], AH-7614, TUG-1506, or TUG-1387. Cells were incubated
with 2.5 mMRenilla luciferase substrate coelenterazine h (Nanolight
Tech, Pinetop, CA) at 37°C for 10 minutes and then stimulated
with various FFA4 agonists for a further 5 minutes at 37°C. BRET
resulting from receptor–b-arrestin-2 interaction was then determined
by measuring the ratio of luminescence at 535 and 475 nm using a
Pherastar FS fitted with the BRET1 optic module (BMG Labtech,
Aylesbury, UK).
Ca21 Mobilization. Calcium assays were carried out on either
Flp-In T-REx 293 cell lines, generated to inducibly express hFFA4
upon treatment with doxycycline, or 1321N1 cells stably expressing
the hFFA1 receptor. One day prior to the experiment, cells were seeded
at 50,000 cells/well (Flp-In REx 293) or 25,000 cells/well (1321N1) in
poly-D-lysine–coated, black, clear-bottom, 96-well microplates. Cells
were allowed to adhere for 3–4 hours before the addition of 100 ng/ml
doxycycline to induce receptor expression in the case of Flp-In T-REx
293 cell lines. The following day, cells were incubated in culture
medium containing the calcium-sensitive dye Fura2-AM (3 mM) for
45 minutes. Cells were then washed three times and then allowed to
equilibrate for 15minutes inHBSSprior to conducting the assay. Fura2
fluorescent emission was measured at 510 nm following excitation at
both 340 and 380 nm during the course of the experiment using a
Flexstation plate reader (Molecular Devices, Brambleside, UK). Cal-
cium responses were then measured as the difference between 340/380
ratios before and after the addition of the relevant compounds. For
antagonism, the cells were preincubated for 15minutes prior to agonist
addition with HBSS supplemented with vehicle [1% (v/v) DMSO],
AH-7614, or TUG-1387 (10 mM) prior to the addition of 50 mM a linolenic
acid (aLA), 500 nM TUG-891, or 13 nM TUG-770.
High-Content Imaging Quantitative Internalization Assay.
hFFA4-mVenus Flp-In T-REx 293 cells were plated 75,000 cells/well
in blackwith clear-bottom96-well plates. Cells were allowed to adhere
for 3–6 hours before the addition of doxycycline (100 ng/ml) to induce
receptor expression. After an overnight incubation, culture medium
was replaced with serum-free DMEM containing the ligand to be
assessed and incubated at 37°C for 30minutes before fixation with 4%
paraformaldehyde. After washingwith phosphate-buffered saline, cell
nuclei were stained for 30 minutes with Hoechst33342.
Plates were subsequently imaged using a Cellomics ArrayScan II
high-content plate imager (Thermo Fisher Scientific, Paisley, UK).
Images were processed to identify internalized mVenus, which was
then normalized to cell number based on nuclei identified by
Hoechst33342 staining, to obtain a quantitative measure of hFFA4-
mVenus internalization.
HTRF-Based Inositol Monophosphate Assay. Inositol mono-
phosphate assays (Cisbio Bioassays, Codolet, France) were performed
according to the manufacturer’s instructions. In brief, a suspension of
7500 cells/well was incubated with the stated concentrations of
agonist for 1 hour in the presence of 10 mM lithium chloride (LiCl).
Inositol monophosphate accumulation was subsequently measured
using a Pherastar FS plate reader.
RNA Isolation and Reverse-Transcription Quantitative Po-
lymerase Chain Reaction (RT-qPCR). Total RNA was isolated
fromC3H10T1/2 cells using an RNEasymini kit (Qiagen,Manchester,
UK). Following RNA isolation, reverse-transcription polymerase
chain reaction was performed using Superscript III (Life Technolo-
gies), and the resultant cDNAwas used as a template for quantitative
polymerase chain reaction analysis using anABI Prism7300 sequence
detector (Applied Biosystems, Paisley, UK). Cycling conditions were
as follows: 50°C for 2 minutes, 95°C for 10 minutes, followed by
40 cycles of 95°C for 15 seconds and 60°C for 1 minute. FFA4, PPARg,
and Runx2 expressions were then defined relative to cyclophilin using
the 22DDCt method.
Western Blotting. Analysis of receptor phosphorylation was
performed on mFFA4-eYFP cells that were pretreated with either
10 mM AH-7614 or TUG-1387 for 30 minutes, after which time they
were treated with 10 mM TUG-891 for 5 minutes. Cell lysates were
prepared and size fractionated on 4–12% SDS-PAGE gels and trans-
ferred to nitrocellulose membranes. Nitrocellulose membranes con-
taining resolved receptor proteins were incubated in Tris-buffered
saline LI-COR blocking buffer (LI-COR Biosciences, Cambridge, UK)
and incubated subsequently with a phospho-specific antiserum pro-
duced in house that is able to recognize phosphorylated Thr347 and
Ser350 residues of the receptor (Prihandoko et al., 2016). Membranes
were air-dried and scanned using an LI-COR Odyssey CLx Imager.
Oil Red O Staining. Untreated or differentiated C3H10T1/2 cells
were fixed in 10% (v/v) formalin for 60 minutes at room temperature.
The cells were washed in 60% (v/v) isopropanol and then incubated for
10 minutes with isopropanol supplemented with 0.6% (w/v) Oil Red O.
The Oil Red O solution (Sigma-Aldrich) was then removed, and cells
were washed 4 with dH2O and then stored in phosphate-buffered
saline at 4°C until visualization using an Invitrogen EVOS FL Auto
ImagingSystem (Life Technologies). After removal of all liquid, theOil
Red O stain was dissolved in isopropanol and the absorbance mea-
sured at 405 nm using a Pherastar FS reader.
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Statistical Analysis. Data are presented as the mean6 S.E.M. of
a minimum of three independent experiments performed in triplicate,
unless otherwise stated in the respective figure legends. Data anal-
ysis was carried out using GraphPad Prism software (package v5.02;
GraphPad Software, La Jolla, CA), with concentration-response data
fitted to three-parameter sigmoidal curves. For allosteric modulation
experiments, data sets were globally fit to an operational model of
allosterism described previously (Hudson et al., 2014). To fit these
data, the t value for all allostericmodulatorswas constrained to reflect
the lack of detectable agonism seen within these compounds, which
allowed for curve fits yielding estimates of loga, logb, logKA, and
logKB. Statistical analyses were carried out using one-way analysis of
variance followed by Tukey’s post-hoc test.
Results
We synthesized and assessed the functional activity of
AH-7614 (Fig. 1), a xanthene derivative of a diarylsulfonamide-
based FFA4 agonist. This compound was originally described as
an antagonist of FFA4, able to block effects of both the poly-
unsaturated v-6 fatty acid linoleic acid and the synthetic FFA4
agonist GSK137647A (Fig. 1) (Sparks et al., 2014), and has since
been used in a number of functional studies (Quesada-López
et al., 2016; Houthuijzen et al., 2017; Villegas-Comonfort et al.,
2017) butwithout analysis of itsmode of action. Indeed,AH-7614
inhibited, in a potent and concentration-dependent manner
(pIC50 vs. EC80 concentrations of the agonists), the ability of
either the v-3 fatty acid aLA (pIC50 7.51 6 0.08, n 5 3) or a
synthetic orthobiphenyl-based agonist of FFA4, TUG-891 (Fig. 1)
(pIC50 8.13 6 0.08, n 5 3) (Shimpukade et al., 2012; Hudson
et al., 2013; Butcher et al., 2014), to promote Ca21mobilization
in Flp-In T-REx 293 cells induced to express hFFA4-eYFP (Fig.
2, A and B). Similar results were obtained when measuring the
ability of AH-7614 to inhibit agonist-induced interactions of
hFFA4 with b-arrestin-2 following coexpression of these two
proteins in HEK293T cells (Fig. 2, C and D). Importantly for
subsequent studies, AH-7614 also functionally antagonized
effects of both aLA and TUG-891 at the corresponding mouse
ortholog of the receptor (mFFA4) (Fig. 2, E and F). AH-7614
showed selectivity for FFA4, as it was unable to antagonize
activation of the other long-chain fatty acid receptor, FFA1
(Milligan et al., 2015, 2017), in studies in which the synthetic
alkyne-basedFFA1 agonist TUG-770 (Christiansen et al., 2013)
promoted elevation of intracellular Ca21 in 1321N1 cells stably
transfected to express a human FFA1 construct (Fig. 2G).
In similar EC80 inhibition experiments, AH-7614 was also
effective in blocking TUG-891–mediated internalization of
FFA4 from the cell surface (Fig. 3A) (pIC505 7.706 0.10,n5 3).
We therefore used this internalization assay, with an endpoint
30 minutes after addition of agonist to facilitate achievement of
ligand equilibrium, to probe the mechanism of AH-7614–
mediatedblockadeofFFA4.Receptor internalizationexperiments
were conducted in which the ability of defined concentrations of
preadded AH-7614 to block internalization in response to various
concentrations of TUG-891 was assessed (Fig. 3B). In these
experiments, it was clear that the primary inhibitory effect of
AH-7614 was to produce a decrease in the maximal response to
Fig. 1. The chemical structures of the FFA4 antagonist AH-7614 and a
range of FFA4 agonists (TUG-891, Cpd A, GSK137647A, and TUG-1197).
Fig. 2. AH-7614 is a potent and selective inhibitor of both human and
murine FFA4 function. Flp-In T-REx 293 cells induced to express hFFA4-
eYFP were pretreated with either vehicle [1% (v/v) DMSO] or increasing
concentrations of AH-7614 for 15 minutes, after which time they were
treated with either 50 mM aLA (A) or 500 nM TUG-891 (B). Both aLA and
TUG-891 induced calcium release that was potently inhibited in the
presence of AH-7614 (aLA, pIC50 = 7.51 6 0.08, n = 3; TUG-891, pIC50 =
8.13 6 0.08, n = 3). HEK293T cells transiently expressing hFFA4-eYFP
and b-arrestin-2-Renilla luciferase were preincubated with either vehicle
[1% (v/v) DMSO] or increasing concentrations of AH-7614. The cells were
then treated with either 50 mM aLA (C) or 500 nM TUG-891 (D), and
b-arrestin-2 recruitment was subsequently determined using a BRET-
based assay. Both aLA and TUG-891 promoted b-arrestin-2 recruitment
that was potently inhibited (aLA, pIC50 = 7.66 6 0.05, n = 5; TUG-891,
pIC50 = 7.55 6 0.07, n = 5) in the presence of increasing concentrations of
AH-7614. mFFA4-dependent b-arrestin-2 recruitment in the presence of
either 50 mM aLA (E) or 500 nM TUG-891 (F) was also potently inhibited
(aLA, pIC50 = 8.05 6 0.08 n = 3; TUG-891, pIC50 = 7.93 6 0.06, n = 3) by
AH-7614. However, AH-7614 had no effect on TUG-770–induced calcium
release in 1321N1 cells stably transfected with hFFA1 receptor (G),
indicating that AH-7614 is not an antagonist at this receptor. Data represent
experiments performed in triplicate three times or more.
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TUG-891. Although this is consistent with outcomes reported by
Sparks et al. (2014) using intracellular Ca21 assays, the longer
time course of the internalization studies largely eliminates
potential issues of ligand hemiequilibrium that can greatly
influence outcomes and mechanistic interpretation in assays,
such as those based on Ca21mobilization, that usemuch shorter
endpoints (Charlton and Vauquelin, 2010). These findings in-
dicated that AH-7614 is not a competitive antagonist of FFA4.
Interestingly, even at the highest concentration of AH-7614
tested, a residual response to TUG-891 remained. This response
toTUG-891was similar in the presence of 1 and 10mMAH-7614,
and as such, the effect of AH-7614 appeared to saturate. Such an
outcome is consistent with AH-7614 functioning as an NAM of
FFA4.
As it is common for small chemical changes in alloste-
ric GPCR ligands to significantly alter the details of their
allosteric behavior (Wood et al., 2011; Hudson et al., 2014), we
next synthesized derivatives of AH-7614 and assessed their
activity at FFA4. Two key derivatives were considered. In the
first, the sulfonamide of AH-7614 was replaced with an amide
(TUG-1387), whereas in the second, the xanthinewas replaced
with a thioxanthene (TUG-1506) (Fig. 4A). These analogswere
tested for their ability to antagonize EC80 concentrations of
TUG-891 (Fig. 4B) in a b-arrestin-2 recruitment assay. The
thioxanthene-containing TUG-1506 retained the ability to
inhibit TUG-891 (pIC50 5 6.38 6 0.09, n 5 3) but with lower
potency than the xanthene containing AH-7614. In contrast,
the amide-containing TUG-1387 lacked all ability to inhibit
TUG-891–mediated activation of FFA4.
As AH-7614, and likely TUG-1506, appeared to be NAMs of
FFA4 function, we characterized and quantified the nature
and extent of their NAM properties against synthetic FFA4
agonists from several distinct chemotypes. A common feature
of GPCR allosteric modulators is that they may show “probe
dependence,” producing different allosteric effects depending
on the orthosteric agonist being modulated (May et al., 2007).
Therefore, we conducted experiments in which AH-7614 (Fig.
5, A–D) and TUG-1506 (Fig. 5, E–H) were used to antago-
nize b-arrestin-2 recruitment to FFA4 induced by synthetic
agonists from each of four distinct chemotypes: TUG-891
(Shimpukade et al., 2012), TUG-1197 (Azevedo et al., 2016),
GSK137647A (Sparks et al., 2014), and Cpd A (Oh et al., 2014)
(Fig. 1). Data from these experiments were then fit to an
operational model of allosterism to quantify the allosteric
effect eachNAMhad on affinity of each orthosteric agonist (a),
the allosteric effect on efficacy of each orthosteric agonist (b),
the affinity of the orthosteric agonists (KA), and the affinity
of the modulator (KB) (Table 1). AH-7614 reduced the maxi-
mal response to each agonist tested, and produced a modest
reduction in agonist potency (Fig. 5, A–D). This corresponded
to loga (Fig. 5I; Table 1) and logb (Fig. 5J; Table 1) values that
were both less than zero for each of the four agonists. However,
although the loga values were broadly similar for each
agonist, the logb for GSK137647A was significantly lower
(P , 0.01) than the value obtained for either TUG-891 or Cpd
A, suggesting a subtle level of probe dependence in AH-7614
modulation of FFA4 activity. This can be noted in the
concentration-response curves by the observation that, al-
though high concentrations of AH-7614 eliminated measure-
able response to GSK137647A (Fig. 5C), a residual response
was apparent for all other agonists, even at 30 mM AH-7614
(Fig. 5, A, B, and D). Importantly, the agonist responses were
similar in the presence of between 3 and 30 mM AH-7614,
indicating that the inhibitory properties of AH-7614 were
saturable, a hallmark of allosteric modulators.
In examining the allosterism between TUG-1506 and the
various FFA4 agonists (Fig. 5, E–H), much more striking
probe dependence was apparent. Most notably, whereas TUG-
1506 primarily shifted the potency of TUG-891 (Fig. 5E) and
Cpd A (Fig. 5H) with little effect on maximal response, the
opposite was true for TUG-1197 and GSK137647A, where
TUG-1506 depressed the maximal response without affecting
agonist potency. This was reflected in the operational model
curve fit parameters for these experiments, where a large
negative loga was observed for TUG-891 and Cpd A (Fig. 5K;
Table 1) but a large negative logb was observed for TUG-1197
and GSK137647A (Fig. 5L; Table 1). This is a clear indication
of the probe dependence in the NAM properties of TUG-1506.
Interestingly, thismay be related to the chemical nature of the
Fig. 3. AH-7614 blocks agonist-induced receptor internalization of the
human FFA4 receptor. Flp-In T-REx 293 cells induced to express hFFA4-
mVenus were pretreated with 10 mMAH-7614 for 15 minutes, after which
time cells were further treated with either vehicle [0.1% (v/v) DMSO]
or TUG-891 (3 mM) for 30 minutes (A) and subsequently fixed. AH-7614
prevented TUG-891 induced receptor internalization (pIC50 = 7.706 0.10).
Cells were pretreatedwith varying concentrations of AH-7614 and exposed
to increasing concentrations of TUG-891 (B) for 30 minutes, after which
theywere fixed. Cells were imaged using a Cellomics ArrayScan II, and the
extent of internalization of the receptor construct was quantified.
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agonists, with TUG-891 and Cpd A both being carboxylate-
based FFA4 agonists, whereas TUG-1197 and GSK137647A
are each sulfonamide-based agonists. Importantly, once
again, the inhibitory effects of TUG-1506 were saturable in
all cases, entirely consistent with defining this compound as
an NAM at FFA4. Similar experiments were also conducted
with TUG-1387 against each FFA4 agonist, although in this
case, given that TUG-1387 had already been shown to lack
activity at FFA4, only a single high concentration of TUG-
1387 was used (Fig. 6, A–D). TUG-1387 did not produce an
NAM effect on TUG-891, TUG-1197, or Cpd A, and only pro-
duced a very modest effect on GSK137647A. Overall, these
results are consistent with either TUG-1387 having no affinity
for FFA4 or it being a silent allostericmodulator that, even if it
does bind the receptor, does not affect orthosteric agonist
function.
To further assess the potential for using AH-7614 in com-
bination with TUG-1387 to define biologic functions of FFA4,
we aimed to confirm the broader ability of AH-7614, but not
TUG-1387, to block additional FFA4 signaling pathways. We
Fig. 4. TUG-1387 and TUG-1506 are chemical derivatives of AH-7614 with varying activity at FFA4. (A) Chemical structures of AH-7614, TUG-1387,
and TUG-1506. HEK293T cells transiently coexpressing hFFA4-eYFP and b-arrestin-2–Renilla luciferase were preincubated with vehicle (0.1% DMSO)
or increasing concentrations of AH-7614, TUG-1387, or TUG-1506. b-Arrestin-2 recruitment to the receptor was then determined in the presence 500 nM
TUG-891 (B). All data represent experiments carried out in triplicate at least three times.
Fig. 5. AH-7614 and TUG-1506 are probe-dependent negative allosteric modulators of FFA4. The nature of AH-7614 (A–D) and TUG-1506 (E–H)
allosteric modulation of FFA4 function was probed by their ability to limit recruitment of b-arrestin-2 to hFFA4-eYFP induced by varying concentrations
of four chemically distinct FFA4 agonists [TUG-891 (A and E), TUG-1197 (B and F), GSK137647A (C and G), and Merck compound A (Cpd A) (D and H)]
using HEK293T cells transiently coexpressing hFFA4-eYFP and b-arrestin-2–Renilla luciferase. Data are fitted to an operational model of allosterism
(Hudson et al., 2014). Estimated parameters for loga and logb are shown for both AH-7614 (I and J) and TUG-1506 (K and L) when assessed at each of the
four agonists. Data shown are from representative experiments (N numbers for each agonist-NAM combination are reported in Table 1) fit to an
operational model of allosterism (Hudson et al., 2014).
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explored both FFA4-mediated accumulation of inositol mono-
phosphates (Fig. 7A) and agonist-induced phosphorylation of
Thr347 and Ser350 residues within the C terminus of FFA4
detected with previously described phospho-FFA4 antisera
(Butcher et al., 2014; Prihandoko et al., 2016) (Fig. 7B). In
each case, the agonist response was functionally inhibited by
AH-7614, but was not affected by TUG-1387. Importantly for
studies on more physiologically relevant systems, we also
found that TUG-1387 lacked activity at the related fatty acid
receptor FFA1 in experiments measuring calcium release in
1321N1-hFFA1 cells (not shown).
Recently, it has been suggested that FFA4 is able to act as a
bipotential regulator of osteogenic and adipogenic differenti-
ation of bone marrow–derived mesenchymal stem cells (Gao
et al., 2015). Furthermore, FFA4 has been proposed to be a key
player in the activation of brown adipose tissue (Quesada-
Lopez et al., 2016), further reinforcing a role for FFA4 in
adipose tissue physiology. To further assess the role of FFA4
in adipogenic differentiation, and to demonstrate the utility of
the FFA4 NAM (AH-7614) when used in combination with
TUG-1387 to interrogate FFA4 biology, we used the murine
mesenchymal stem cell line C3H10T1/2 (Tang et al., 2004;
TABLE 1
Operational model curve-fit parameters for AH-7614 and TUG-1506
Agonist loga logb pKA pKB N
AH-7614
TUG-891 20.80 6 0.11 20.77 6 0.09 6.77 6 0.14 7.98 6 0.24 4
TUG-1197 20.52 6 0.09 21.08 6 0.10 6.44 6 0.05 7.82 6 0.26 5
GSK137647A 20.58 6 0.09 21.54 6 0.14 6.32 6 0.04 8.14 6 0.21 3
Cpd A 20.80 6 0.14 20.66 6 0.15 6.31 6 0.22 8.17 6 0.26 3
TUG-1506
TUG-891 21.68 6 0.17 20.18 6 0.10 6.79 6 0.11 7.46 6 0.06 4
TUG-1197 20.48 6 0.12 21.34 6 0.13 6.48 6 0.08 6.90 6 0.04 3
GSK137647A 20.44 6 0.07 21.24 6 0.11 6.44 6 0.03 7.04 6 0.10 3
Cpd A 22.15 6 0.36 0.06 6 0.11 6.46 6 0.18 7.28 6 0.02 3
Fig. 6. TUG-1387 does not antagonize the effects of distinct FFA4 agonist chemotypes. HEK293T cells transiently expressing mFFA4-eYFP and
b-arrestin-2–Renilla luciferase constructs were pretreated for 30 minutes with vehicle, 10 mM AH-7614, or 10 mM TUG-1387. They were then treated
with TUG-891 (A), Cpd A (B), GSK137647A (C), or TUG-1197 (D) to assess receptor-mediated arrestin recruitment. AH-7614 was able to block b-arrestin-
2 recruitment in all cases, whereas TUG-1387 did not have any effect except to produce a small but significant (**P , 0.001) reduction of the efficacy of
GSK137647A (C). Data represent experiments performed in triplicate three/four times. mBRET, units are equal to the 535/475 nm emission ratio
multiplied by 1000.
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Hashimoto et al., 2016; Lee et al., 2016). Here, differentiation
toward an adipocyte phenotype was produced by maintaining
the cells in the presence of an induction mixture (IID)
consisting of 100 nM insulin, 500 mM IBMX, and 10 nM
dexamethasone for 5 days. Oil Red O staining effectively
visualized the development of triglyceride deposits associated
with adipogenesis (Fig. 8A). In concert, exposure to the IID-
containing medium produced clear upregulation of mRNA for
the adipogenic development marker, PPARg (Fig. 8B). This
effect was not produced simply by cell confluence on the tissue
culture plate (Fig. 8B). In parallel, levels of Runt-related
transcription factor 2 (Runx2) mRNA, a key transcription
factor associated with osteoblast differentiation (Xu et al.,
2015; Yuan et al., 2016), were greatly reduced (Fig. 8C). Over
this time, frame levels of mFFA4 mRNA were also markedly
increased by cell maintenance in the IID medium; interest-
ingly, however, an equivalent upregulation of mFFA4 mRNA
was also produced simply by maintaining C3H10T1/2 cells
at confluence for a 5-day period (Fig. 8D). The ability of
C3H10T1/2 cells to differentiate toward the adipocyte pheno-
type was clearly dependent upon signaling from FFA4,
because treatment of cells with AH-7614 along with the IID
medium greatly reduced visual observation of triglyceride
stores as detected by Oil Red O staining and its quantification
(Fig. 9, A and B). Treatment with AH-7614 also limited IID-
induced PPARg mRNA induction (Fig. 9C), without affecting
the associated downregulation of Runx2 expression (Fig. 9D).
In contrast, treatment of C3H10T1/2 cells with TUG-1387
during the induction period with the IID-containing medium
had no significant effect on the development of Oil Red O
staining (Fig. 9, A and B). Taken together, these data indicate
that TUG-1387, although structurally related, lacks activity
at both FFA4 and the related FFA1, and therefore indicate
this compoundwill be a useful chemical control to confirm that
biologic effects produced by AH-7614 and related compounds,
such as TUG-1506, are in fact FFA4-mediated.
Discussion
The availability of pharmacological tool compounds is
central to efforts to define functions of many cellular proteins,
including GPCRs, and to assess such proteins as potential
therapeutic targets. However, for poorly and recently charac-
terized receptors, such tool compounds are often lacking;
described largely in the chemical/patent literature and, there-
fore, often of limited availability; and/or are poorly character-
ized in terms of selectivity and potential off-target effects.
Within the group of GPCRs that respond to nonesterified, or
“free,” fatty acids, the most broad-reaching pharmacopoeia to
date targets the long-chain fatty acid receptor FFA1 (Milligan
et al., 2017). This reflects that FFA1 has been targeted
therapeutically and in human clinical trials to assess whether
activation of this receptor might provide an approach to treat
type II diabetes (Watterson et al., 2014; Li et al., 2016;
Mohammad, 2016; Ghislain and Poitout, 2017). Although the
second GPCR that is activated by longer-chain free fatty acids,
FFA4, is also frequently suggested as a potential therapeutic
target for diabetes and other metabolic disorders (Li et al.,
2016; Moniri, 2016; Hansen and Ulven, 2017), this lags
behind studies on FFA1, and no synthetic ligands with
activity at this receptor have yet entered clinical studies
(Milligan et al., 2017). As a result, even tool compounds that
are useful for assessing roles of this receptor are less widely
available or understood (Hansen and Ulven, 2017). More-
over, as clear consensus is based on the therapeutic potential
of agonism of FFA4 (Li et al., 2016; Moniri, 2016), little effort
Fig. 7. AH-7614, but not TUG-1387, blocks
agonist-induced elevation of intracellular
inositol monophosphates and phosphoryla-
tion of FFA4. (A) FFA4-mediated inositol
monophosphate (IP1) production was mea-
sured in cells expressing hFFA4-mVenus.
TUG-891 (closed circles) promoted accu-
mulation of IP1. Pretreatment with either
10 mM AH-7614 (inverted triangles) or in-
creasing concentrations of this molecule (open
squares) blocked IP1 accumulation. By con-
trast, pretreatment with TUG-1387 was
without effect (open diamonds). (B) mFFA4-
eYFP cells were pretreated with vehicle or
various concentrations of AH-7614 or TUG-
1387 for 30 minutes followed by treatment
with 10 mM TUG-891 for 5 minutes. Cell
lysates were prepared and resolved by SDS-
PAGE and immunoblotted with an mFFA4-
specific phospho-antiserum that recognizes
phosphorylation of residues Thr347 and Ser350
(Prihandoko et al., 2016). Quantification of
a series of such immunoblots is shown in the
right-hand panel. ns, P . 0.05.
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has been expended to identify, report, or characterize antag-
onists of this receptor, despite antagonist tool compounds
being a traditional touchstone for detailed pharmacological
analysis.
The only inhibitor of FFA4 function reported to date is
AH-7614 (Sparks et al., 2014). Although Sparks et al. (2014)
suggested that this compound would likely act as a compet-
itive antagonist of FFA4, the limited data presented in their
Fig. 8. mRNA levels of FFA4 and PPARg are upregulated in C3H10T1/2 cells by differentiation toward the adipocyte phenotype. (A) C3H10T1/2 cells
were differentiated toward an adipocyte phenotype by treatment with IIDmedium. Confirmation of effective differentiation after 5 days of treatment
was obtained by staining for triglyceride droplets within the cells using Oil Red O. RT-qPCR was performed to assess changes in expression levels
of PPARg (B), Runx2 (C), and mFFA4 (D) under conditions of subconfluence, confluence, 5 days postconfluence, and 5 days postconfluence in
the presence of IID. Data are presented as the group mean6 S.E.M. of three independent experiments (*different at P, 0.05, **P, 0.01, and ***P,
0.001). Scale bar in (A) = 400 mm.
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report did not actually suggest such a mode of action, which
appeared to be noncompetitive, at least in assays measuring
regulation of intracellular Ca21 levels. The studies reported
here expand on this, defining AH-7614 as an NAM of FFA4
function. This conclusion is supported by several hallmarks
of allosterism (May et al., 2007), including that the ability
of AH-7614 to inhibit FFA4 function is saturable, and that
AH-7614 displays some level of probe dependence. More
striking, however, in this regard is the chemical derivative of
AH-7614, TUG-1506, described for the first time in these
studies, which shows clear probe dependence depending on
the chemical nature of the FFA4 agonist it is modulating.
Specifically, this compound is anNAMprimarily of ligand affinity
for the two carboxylate-containing agonists tested, but primarily
an NAM of efficacy for the noncarboxylate, sulphonamide-based
agonists. Such changes in allosteric modulation are commonly
observed with small chemical changes in allosteric ligands (Wood
et al., 2011; Hudson et al., 2014), and indeed, the observed pat-
tern of inhibition by both AH-7614 and TUG-1506 can only be
explained by an allosteric mode of action.
Fig. 9. Adipocyte differentiation of C3H10T1/2 cells requires FFA4 signaling. (A) C3H10T1/2 cells were differentiated (IID) in the presence of vehicle
(0.1% DMSO), 10 mMAH-7614, or 10 mM TUG-1387 compared with a nondifferentiated control and then stained with Oil Red O. (B) Oil Red O staining
was subsequently dissolved in isopropanol and then quantified bymeasuring absorbance at 405 nm (n = 10, data presented as mean6 S.E.M.). RT-qPCR
analysis of PPARg (n = 5) (C) and Runx2 (n = 4) (D) levels was then performed on differentiated (IID) and nondifferentiated (vehicle) C3H10T1/2 cells in
the presence or absence of 10 mM AH-7614. Data are presented as the mean 6 S.E. (**P , 0.01, and ***P , 0.001). Scale bar in (A) = 400 mm.
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Whereas Sparks et al. (2014) more broadly assessed the
selectivity of the FFA4 agonist GSK137647A described in
their study, they did not extend this to AH-7614. Therefore,
having identified TUG-1387 in the current work as a close
structural analog of AH-7614 that lacks activity at FFA4, we
used each of these ligands to define specific roles for FFA4.
Indeed, the FFA4 NAM AH-7614 prevents differentiation of
a mouse mesenchymal stem cell line toward an adipocyte
phenotype, and does so in a manner that is consistent with
blockade of endogenous signaling via FFA4.
We describe AH-7614 and TUG-1506 as the first allosteric
ligands for the FFA4 receptor. Despite only a minor structural
difference between these two compounds, substantial differ-
ences in the nature of their allosterism were observed, per-
haps suggesting that further examination of the structure
activity relationship within the AH-7614 chemical series may
yield novel allosteric FFA4 ligands with diverse pharmaco-
logical properties. The fact that the observed NAM properties
within the AH-7614 series were clearly probe dependent
indicates that care must be taken when designing future
studies using these ligands. Overall, with appropriate caution,
AH-7614 should prove to be a valuable tool in further un-
raveling functions of the FFA4 receptor.
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